Advertisement

Pharmaceutisch Weekblad

, Volume 12, Issue 2, pp 71–74 | Cite as

Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses

  • E. W. Wuis
  • M. J. M. Dirks
  • T. B. Vree
  • E. Van der Kleijn
Short Communications

Abstract

The pharmacokinetics of racemic baclofen as determined from plasma and urine data in six spastic patients treated with individualized oral doses, 30–80 mg daily, are presented. Peak plasma concentrations were achieved 1.9 h (±0.7) after a dose. The fluctuation in the plasma concentration was great, ranging from 188 to 439%. The total body clearance averaged 175 ml·min−1 (±44), plasma protein binding 35% (±6). Baclofen was for the greater part excreted unchanged by the kidney, 65% (±16). Its apparent renal clearance equalled the creatinine clearance. The contribution of the renal clearance to the total body clearance can explain the previously described toxicity when renal impairment is present. The results agree with earlier reports on single doses in healthy subjects.

Keywords

Baclofen Clearance Patients Pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kochak GM, Rakhit A, Wagner WE, Honc F, Waldes L, Kershaw RA. The pharmacokinetics of baclofen derived from intestinal infusion. Clin Pharmacol Ther 1985;38:251–7.PubMedGoogle Scholar
  2. 2.
    Peterson GM, McLean S, Millingen KS. Food does not affect the bioavailability of baclofen. Med J Aust 1985;42:689–90.Google Scholar
  3. 3.
    Krauss D. Untersuchungen zur Razemat- und Enantiomerenkinetik von Baclofen und seinen Fluoranalogons [Disssertation]. Frankfurt am Main: Goethe-Universität, 1988.Google Scholar
  4. 4.
    Wuis EW, Dirks MJM, Vree TB, Van der Kleijn E. Plasma and urinary excretion kinetics of orally administered baclofen in healthy subjects. Eur J Clin Pharmacol 1989;37:181–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Hulme A, MacLennan WJ, Ritchie RT, John VA, Shotton PA. Baclofen in the elderly stroke patient its side effects and pharmacokinetics. Eur J Clin Pharmacol 1985;29:467–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Wuis EW, Dirks RJM, Vree TB, Van der Kleijn E. High-performance liquid chromatographic analysis of baclofen in plasma and urine of man after precolumn extraction and derivatization witho-phthaldialdehyde. J Chromatogr 1985;337:341–50.PubMedGoogle Scholar
  7. 7.
    Wuis EW, Van Beijsterveldt LEC, Dirks RJM, Vree TB, Van der Kleijn E. Rapid simultaneous determination of baclofen and its γ-hydroxy metabolite in urine by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1987;420:212–6.PubMedGoogle Scholar
  8. 8.
    Garabedian-Ruffalo SM, Ruffalo RL. Adverse effects secondary to baclofen-withdrawal. Drug Intell Clin Pharm 1985;19:304–6.PubMedGoogle Scholar
  9. 9.
    Harrison SA, Wood Jr CA. Hallucinations after preoperative baclofen discontinuation in spinal cord injury patients. Drug Intell Clin Pharm 1985;19:747–9.PubMedGoogle Scholar
  10. 10.
    Young RR, Delwaide PJ. Drug therapy. Spasticity. II. N Engl J Med 1981;304:96–9.PubMedGoogle Scholar
  11. 11.
    Seyfert S, Kraft D, Wagner K. Baclofen-Dosis bei Haemodialyse und Niereninsuffizienz. Nervenarzt 1981;52:616–7.PubMedGoogle Scholar
  12. 12.
    Anderson P, Nohér H, Swahn CG. Pharmacokinetics in baclofen overdose. Clin Toxicol 1984;22:11–20.Google Scholar
  13. 13.
    Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;320:1517–21.PubMedGoogle Scholar
  14. 14.
    Dahlin PA, George J. Baclofen toxicity associated with declining renal clearance after ibuprofen. Drug Intell Clin Pharm 1984;18:805–8.PubMedGoogle Scholar
  15. 15.
    Hormes JT, Benarroch EE, Rodriguez M, Klass DW. Periodic sharp waves in baclofen-induced encephalopathy. Arch Neurol 1988;45:814–5.PubMedGoogle Scholar
  16. 16.
    Pedersen E. How spasticity affects bowel and bladder function. In: Feldman RG, Young RR, Koella WP, eds. Spasticity. Disordered motor control. Chicago: Year Book Medical Publishers, 1980:57–69.Google Scholar
  17. 17.
    Wuis EW, Dirks MJM, Termond EFS, Vree TB, Van der Kleijn E. Comparison of the pharmacokinetics of intravenously administered rac-baclofen and its (−)-(R)- and (+)-(S)-enantiomers in dogs. Int J Clin Pharm Res 1989;10:239–46.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1990

Authors and Affiliations

  • E. W. Wuis
    • 1
  • M. J. M. Dirks
    • 1
  • T. B. Vree
    • 1
  • E. Van der Kleijn
    • 1
  1. 1.Department of Clinical PharmacyUniversity Hospital Nijmegen Sint RadboudHB NijmegenThe Netherlands

Personalised recommendations